CA9, CYFIP2 and LGALS3BP-A Novel Biomarker Panel to Aid Prognostication in Glioma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Mar 13

PMID 38473425

Authors

Amanda L Hudson

Angela Cho

Emily K Colvin

Sarah A Hayes

Helen R Wheeler

Viive M Howell

Affiliations

Soon will be listed here.

Abstract

Brain cancer is a devastating and life-changing disease. Biomarkers are becoming increasingly important in addressing clinical issues, including in monitoring tumour progression and assessing survival and treatment response. The goal of this study was to identify prognostic biomarkers associated with glioma progression. Discovery proteomic analysis was performed on a small cohort of astrocytomas that were diagnosed as low-grade and recurred at a higher grade. Six proteins were chosen to be validated further in a larger cohort. Three proteins, CA9, CYFIP2, and LGALS3BP, were found to be associated with glioma progression and, in univariate analysis, could be used as prognostic markers. However, according to the results of multivariate analysis, these did not remain significant. These three proteins were then combined into a three-protein panel. This panel had a specificity and sensitivity of 0.7459 for distinguishing between long and short survival. In silico data confirmed the prognostic significance of this panel.

References

Laubli H, Alisson-Silva F, Stanczak M, Siddiqui S, Deng L, Verhagen A . Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem. 2014; 289(48):33481-91. PMC: 4246102. DOI: 10.1074/jbc.M114.593129. View

Zheng T, Liu Q, Xing F, Zeng C, Wang W . Disulfidptosis: a new form of programmed cell death. J Exp Clin Cancer Res. 2023; 42(1):137. PMC: 10230712. DOI: 10.1186/s13046-023-02712-2. View

Jawhari S, Ratinaud M, Verdier M . Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'. Cell Death Dis. 2016; 7(10):e2434. PMC: 5133985. DOI: 10.1038/cddis.2016.318. View

De Rosa A, Pellegatta S, Rossi M, Tunici P, Magnoni L, Speranza M . A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One. 2013; 7(12):e52113. PMC: 3528762. DOI: 10.1371/journal.pone.0052113. View

Peng Q, Ren B, Xin K, Liu W, Alam M, Yang Y . CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers. Eur J Med Res. 2023; 28(1):364. PMC: 10515071. DOI: 10.1186/s40001-023-01366-2. View

Chen Z, Zhang Z, Ding W, Zhang J, Tan Z, Mei Y . Expression and Potential Biomarkers of Regulators for M7G RNA Modification in Gliomas. Front Neurol. 2022; 13:886246. PMC: 9124973. DOI: 10.3389/fneur.2022.886246. View

Brown K, Toker A . The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep. 2015; 7:13. PMC: 4335789. DOI: 10.12703/P7-13. View

Wang S, Cheng Y, Zheng Y, He Z, Chen W, Zhou W . PRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma. Sci Rep. 2016; 6:39630. PMC: 5171641. DOI: 10.1038/srep39630. View

Proescholdt M, Merrill M, Stoerr E, Lohmeier A, Pohl F, Brawanski A . Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol. 2012; 14(11):1357-66. PMC: 3480266. DOI: 10.1093/neuonc/nos216. View

10.

Chia S, Wykoff C, Watson P, Han C, Leek R, Pastorek J . Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001; 19(16):3660-8. DOI: 10.1200/JCO.2001.19.16.3660. View

11.

White M, Roife D, Gomer R . Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation. J Immunol. 2015; 195(4):1858-67. PMC: 4530092. DOI: 10.4049/jimmunol.1500365. View

12.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

13.

Deng X, Das S, Kaur H, Wilson E, Camphausen K, Shankavaram U . Glioma-BioDP: database for visualization of molecular profiles to improve prognosis of brain cancer. BMC Med Genomics. 2023; 16(1):168. PMC: 10350252. DOI: 10.1186/s12920-023-01593-w. View

14.

Capone E, Iacobelli S, Sala G . Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. J Transl Med. 2021; 19(1):405. PMC: 8474792. DOI: 10.1186/s12967-021-03085-w. View

15.

Bui M, Seligson D, Han K, Pantuck A, Dorey F, Huang Y . Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003; 9(2):802-11. View

16.

Haapasalo J, Nordfors K, Hilvo M, Rantala I, Soini Y, Parkkila A . Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res. 2006; 12(2):473-7. DOI: 10.1158/1078-0432.CCR-05-0848. View

17.

Jiao S, Li N, Cai S, Guo H, Wen Y . Inhibition of CYFIP2 promotes gastric cancer cell proliferation and chemoresistance to 5-fluorouracil through activation of the Akt signaling pathway. Oncol Lett. 2017; 13(4):2133-2140. PMC: 5403719. DOI: 10.3892/ol.2017.5743. View

18.

Cordero A, Kanojia D, Miska J, Panek W, Xiao A, Han Y . FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis. Oncogene. 2019; 38(37):6445-6460. PMC: 6742563. DOI: 10.1038/s41388-019-0893-4. View

19.

Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen Z, Tucholska M . The plasma peptides of ovarian cancer. Clin Proteomics. 2019; 15:41. PMC: 6302491. DOI: 10.1186/s12014-018-9215-z. View

20.

Xu X, Wang Z, Liu N, Cheng Y, Jin W, Zhang P . Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ. Int J Oncol. 2018; 53(1):189-202. DOI: 10.3892/ijo.2018.4382. View